Literature DB >> 17555452

Intensity of HLA class I expression and KIR-mismatch determine NK-cell mediated lysis of leukaemic blasts from children with acute lymphatic leukaemia.

Matthias Pfeiffer1, Michael Schumm, Tobias Feuchtinger, Klaus Dietz, Rupert Handgretinger, Peter Lang.   

Abstract

The impact of human leucocyte antigen (HLA) class I expression intensity and killer-cell immunoglobulin-like receptor (KIR)-mismatch was investigated on natural killer (NK)-cell mediated lysis of B-lineage leukaemic blasts from 21 paediatric patients in vitro. Blast susceptibility to standardised NK-activity and HLA-expression differed widely. A clear association between HLA-molecules/cell (range 442 000-13 000) and specific lysis (mean 59%, range 13-98%) was observed (r(2) = 0.68). A compound model incorporating HLA-expression and KIR-ligand-mismatch provided an even stronger association (r(2) = 0.87), whereas KIR-ligand-mismatch alone was not significant. Assessment of these factors might identify patients who could benefit from NK-mediated graft-versus-leukaemia effects after mismatched stem cell transplantation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17555452     DOI: 10.1111/j.1365-2141.2007.06631.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  13 in total

Review 1.  Engineering Natural Killer Cells for Cancer Immunotherapy.

Authors:  Katayoun Rezvani; Rayne Rouce; Enli Liu; Elizabeth Shpall
Journal:  Mol Ther       Date:  2017-06-28       Impact factor: 11.454

Review 2.  Current and future management strategies for relapsed or progressive hepatoblastoma.

Authors:  Rajkumar Venkatramani; Wayne L Furman; Joerg Fuchs; Steven W Warmann; Marcio H Malogolowkin
Journal:  Paediatr Drugs       Date:  2012-08-01       Impact factor: 3.022

3.  Reconstitution of natural killer cell receptors influences natural killer activity and relapse rate after haploidentical transplantation of T- and B-cell depleted grafts in children.

Authors:  Matthias M Pfeiffer; Tobias Feuchtinger; Heiko-Manuel Teltschik; Michael Schumm; Ingo Müller; Rupert Handgretinger; Peter Lang
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

Review 4.  Recent advances in hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia.

Authors:  Veronica Jude; Ka Wah Chan
Journal:  Curr Hematol Malig Rep       Date:  2010-07       Impact factor: 3.952

5.  Tumor-priming converts NK cells to memory-like NK cells.

Authors:  Marina Pal; Lisa Schwab; Anastasiya Yermakova; Emily M Mace; Rainer Claus; Ann-Christin Krahl; Jeanette Woiterski; Udo F Hartwig; Jordan S Orange; Rupert Handgretinger; Maya C André
Journal:  Oncoimmunology       Date:  2017-04-18       Impact factor: 8.110

6.  HLA-E expression constitutes a novel determinant for ALL disease monitoring following hematopoietic stem cell transplantation.

Authors:  Markus Uhrberg; Florian Babor; Sarah B Reusing; Angela R Manser; Stefanie Groeneveld-Krentz; Vera Rebmann; Peter A Horn; Roland Meisel; Leonid Karawajew; Arndt Borkhardt
Journal:  Bone Marrow Transplant       Date:  2021-03-03       Impact factor: 5.483

Review 7.  Natural killer cells in human cancer: from biological functions to clinical applications.

Authors:  Estrella Mariel Levy; María Paula Roberti; José Mordoh
Journal:  J Biomed Biotechnol       Date:  2011-04-26

8.  Influence of Histone Deacetylase Inhibitors and DNA-Methyltransferase Inhibitors on the NK Cell-Mediated Lysis of Pediatric B-Lineage Leukemia.

Authors:  Matthias Manuel Pfeiffer; Helen Burow; Sabine Schleicher; Rupert Handgretinger; Peter Lang
Journal:  Front Oncol       Date:  2013-04-29       Impact factor: 6.244

9.  NKG2D Signaling Leads to NK Cell Mediated Lysis of Childhood AML.

Authors:  Patrick Schlegel; Kerstin Ditthard; Peter Lang; Markus Mezger; Sebastian Michaelis; Rupert Handgretinger; Matthias Pfeiffer
Journal:  J Immunol Res       Date:  2015-07-08       Impact factor: 4.818

Review 10.  The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer.

Authors:  Katayoun Rezvani; Rayne H Rouce
Journal:  Front Immunol       Date:  2015-11-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.